

FEB. 1. 2006 2:38PM

AVENTIS US PAT DEPT

NO. 1572. P. 3  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
E. Kostenis et al.

Examiner: S. Priebe

**RECEIVED**  
**CENTRAL FAX CENTER**

Application No.: 10/706,763

Art Unit: 1633

**FEB 01 2006**

Filed: November 12, 2003

**TELEFAX CERTIFICATE**

Title: Use of EDG2 Receptor in An Animal Model  
of Heart Failure

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for Patents,  
Alexandria, VA 22313, on

Feb 1, 2006  
Date of Transmission

[Signature]  
Signature

**RESPONSE TO OFFICE COMMUNICATION**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication dated October 20, 2005 in the above-referenced application, applicants elect Group I, claims 1-8, drawn to mammalian myocardial cells transfected with an adenoviral vector encoding EDG2 and a marker, classified in class 435, subclass 325. Applicants reserve the right to file one or more divisional applications directed to the non-elected subject matter in this application.

A request for a three-month extension of time and the required fee accompany this amendment, extending the period of reply to February 20, 2006. The Commissioner is authorized to charge the \$1020 (three-month extension fee) or any additional fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,

[Signature]  
Xuhong Sunny Wang, Reg. No. 54,524  
Patent Agent for Applicant

Sanofi-Aventis Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807  
Telephone (908) 231-3648  
Telefax (908) 231-2626  
Docket No. DEAV2002/0083 US NP